Intraarterial Verapamil for Neuroprotection in Ischemic Stroke

Who is this study for? Adult patients with Ischemic Stroke
What treatments are being studied? Verapamil
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Written informed consent

• 18 years of age and over

• Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia

• Candidate for mechanical thrombectomy procedure

• Onset of symptoms less than 8 hours

• Measurable neurologic deficit (NIHSS ≥4)

• Willingness to follow up with rehabilitation therapy

• Anticipated life expectancy of at least 3 months

Locations
United States
New Jersey
AtlantiCare Regional Medical Center
RECRUITING
Atlantic City
Pennsylvania
St Mary Medical Center
NOT_YET_RECRUITING
Langhorne
Crozer Chester Medical Center
COMPLETED
Upland
Time Frame
Start Date: 2017-04-20
Estimated Completion Date: 2026-12
Participants
Target number of participants: 60
Treatments
Experimental: Verapamil 10 mg Treatment Group
Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (10 mg) Verapamil.
Experimental: Verapamil 20 mg Treatment Group
Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (20 mg) Verapamil.
Related Therapeutic Areas
Sponsors
Leads: Global Neurosciences Institute

This content was sourced from clinicaltrials.gov